In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model

被引:43
作者
Allen, GP
Kaatz, GW
Rybak, MJ [1 ]
机构
[1] Wayne State Univ, Eugene Appelbaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Detroit, MI 48201 USA
[3] John D Dingell VA Med Ctr, Detroit, MI 48201 USA
关键词
mutant prevention concentration; fluoroquinolones; Staphylococcus aureus; antimicrobial resistance;
D O I
10.1016/j.ijantimicag.2004.03.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To test the validity of the mutant selection window, we simulated mutant prevention concentration-targeted fluoroquinolone concentrations using an in vitro model with infected fibrin clots. Therapeutic ciprofloxacin (peak 5 mug/mL; t(1/2) 4 h), gatifloxacin (3.5 mug/mL; 8 h), gemifloxacin (1.25 mug/mL; 8 h), levofloxacin (6 mug/mL; 6 h) and moxifloxacin (4.5 mug/mL; 12 h) were tested against methicillin-susceptible and -resistant Staphylococcus aureus, as were mutant prevention concentration (MPC)-targeted regimens achieving a trough of 1/4x or 2x MPC. MIC/MPC for MSSA K553 were 0.125/2, 0.03/0.125, 0.03/0.063, 0.125/1 and 0.015/0.25 mug/mL for ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin, respectively. Corresponding values for MRSA 494 were 0.125/1, 0.063/0.125, 0.03/0.063, 0.125/0.5 and 0.063/0.125 mug/mL. All regimens produced efflux mutants of MSSA K553. For MRSA 494, therapeutic and 1/4x MPC levofloxacin regimens produced resistance, whereas only 1/4x MPC regimens of gatifloxacin, gemifloxacin, and moxifloxacin produced resistance. All ciprofloxacin regimens produced resistance. Ciprofloxacin 1/4x MPC and therapeutic levofloxacin caused outgrowth of GrlA mutants (S80Y amino acid substitution); efflux mutants were isolated in all other cases. Overall, gatifloxacin, gemifloxacin, and moxifloxacin displayed a lesser propensity to select resistant isolates of S. aureus than ciprofloxacin and levofloxacin. The mutant selection window premise appeared valid for MRSA only. Additional studies are necessary to define the applicability of the MPC. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:150 / 160
页数:11
相关论文
共 30 条
[1]   Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].
Allen, GP ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614
[2]  
ALLEN GP, 2001, 22 INT C CHEM AMST N, P73
[3]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[4]   THE FLUOROQUINOLONES AS TREATMENT FOR INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA [J].
CRUCIANI, M ;
BASSETTI, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (03) :403-417
[5]   Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus [J].
Dong, YZ ;
Zhao, XL ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1756-1758
[6]   Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance [J].
Dong, YZ ;
Xu, C ;
Zhao, XL ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2978-2984
[7]   CLONING AND PRIMARY STRUCTURE OF STAPHYLOCOCCUS-AUREUS DNA TOPOISOMERASE-IV - A PRIMARY TARGET OF FLUOROQUINOLONES [J].
FERRERO, L ;
CAMERON, B ;
MANSE, B ;
LAGNEAUX, D ;
CROUZET, J ;
FAMECHON, A ;
BLANCHE, F .
MOLECULAR MICROBIOLOGY, 1994, 13 (04) :641-653
[8]   In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus [J].
Firsov, AA ;
Vostrov, SN ;
Lubenko, IY ;
Drlica, K ;
Portnoy, YA ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1604-1613
[9]   Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae [J].
Fukuda, H ;
Kishii, R ;
Takei, M ;
Hosaka, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1649-1653
[10]   Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials [J].
Graffunder, EM ;
Venezia, RA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (06) :999-1005